Crystalline forms of MNK inhibitors
US11130757B2 · kind B2 · utility
2Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 23, 2019 |
| Grant date | Sep 28, 2021 |
| Priority date | — |
| Expiry date | Oct 23, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.